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A population-based early detection program for breast cancer has been in progress in 
Finland since 1987. According to regulations during the study period 1987-2001, free of 
charge mammography screening was offered every second year to women aged 50-59 
years. Recently, the screening service was decided to be extended to age group 50-69. 
However, the scope of the program is still frequently discussed in public and information 
about potential impacts of mass-screening practice hanges on future breast cancer burden 
is required.  
 
The aim of this doctoral thesis is to present methodologies for taking into account the mass-
screening invitation information in breast cancer burden predictions, and to present 
alternative breast cancer incidence and mortality predictions up to 2012 based on scenarios 
of the future screening policy. The focus of this work is not on assessing the absolute 
efficacy but the effectiveness of mass-screening, ad by utilizing the data on invitations, on 
showing the estimated impacts of changes in an existing creening program on the short-
term predictions.  
 
The breast cancer mortality predictions are calculated using a model that combines 
incidence, cause-specific and other cause survival on individual level. The screening 
invitation data are incorporated into modeling of breast cancer incidence and survival by 
dividing the program into separate components (first and subsequent rounds and years 
within them, breaks, and post screening period) and defining a variable that gives the 
component of the screening program. The incidence is modeled using a Poisson regression 
approach and the breast cancer survival by applying a parametric mixture cure model, 
where the patient population is allowed to be a combination of cured and uncured patients. 
The patients’ risk to die from other causes than breast cancer is allowed to differ from that 
of a corresponding general population group and to depend on age and follow-up time.  
 
As a result, the effects of separate components of the screening program on incidence, 
proportion of cured and the survival of the uncured are quantified. According to the 
predictions, the impacts of policy changes, like extending the program from age group 50-
59 to 50-69, are clearly visible on incidence while th  effects on mortality in age group 40-
74 are minor. Extending the screening service would increase the incidence of localized 
breast cancers but decrease the rates of non-localized breast cancer. There were no major 
differences between mortality predictions yielded by alternative future scenarios of the 
screening policy: Any policy change would have at the most a 3.0% reduction on overall 
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BMI  Body mass index = weight(kg)/ height(m)2 
CI  Confidence interval 
DCIS  Ductal carcinoma in situ tumor, a non-invasive breast carcinoma 
EUROCARE European cancer registry–based project on the survival and care of patients 
with cancer 
HRT  Hormone replacement therapy 
IARC International Agency for Research on Cancer (WHO’s cancer research 
institute) 





List of original publications 
 
 
I  Seppänen J, Heinävaara S, Hakulinen T. Influence of alternative mammographic 
screening scenarios on breast cancer incidence predictions. Cancer Causes and 
Control 2006; 17:1135-1144. 
 
II Seppänen J, Heinävaara S, Anttila A, Sarkeala T, Virkkunen H, Hakulinen T. Effects 
of different phases of an invitational screening programme on breast cancer 
incidence. International Journal of Cancer 2006; 119:920-924. 
 
III Seppänen J, Heinävaara S, Hakulinen T. Predicting impacts of mass-screening policy 
changes on breast cancer mortality. Statistics in Medicine 2008; 27. Published Online 
9.7.2008. 
 
IV Seppänen J, Heinävaara S, Holli K, Hakulinen T. Comparison of cancer registry and 
clinical data as predictors for breast cancer survival. Cancer Causes and Control 




These publications will be cited in the text by their Roman numerals. 
 
 
These original publications have been reprinted with kind permission of the copyright 









Breast cancer is the most common cancer among women in Europe and also world wide in 
developed countries [1, 2]. In Finland, breast cancer was responsible for 31.1% of all new 
cancer cases and 16.8% of cancer deaths among women in year 2006 
(www.cancerregistry.fi). The number of new cases has been strikingly increasing during the 
past decades, and even if the age-specific rates remain d constant, the ageing of the Finnish 
population will cause continuous increase of new cases in the future. However, due to 
improved treatments and an effective early detection program [3-7], the recent breast 
cancer mortality shows a constant trend, see Figure 1. 
 
Figure 1: Age-adjusted (world standard) breast cancer incidence and 
mortality rates for Finnish women in time period 1959-2006. Data are from 
the Finnish Cancer Registry [www.cancerregistry.fi ]. 
 
 
Breast cancer is one of the cancer sites subjected to the most extensive research. Well 
confirmed risk factors for breast cancer are reproductive factors (high age at first 
childbearing, early menarche, late menopause, few children, short breastfeeding period), 
use of HRT, genetic susceptibility, ionizing radiation, high breast density, and previous 
benign breast diseases [8]. There is also some evidence that some lifestyle factors such as 
low pre-menopausal or high postmenopausal BMI, high consumption of alcohol and low 
physical activity would increase the risk of breast cancer, but, except alcohol, their 
association appears to be weaker than that of the reproductive factors. Therefore, as many 
of the known risk factors are biological in nature o  otherwise not relevant to be controlled 







Mammographic screening aims to find tumors in an early, detectable preclinical phase, and 
the core concept is to bring the diagnosis and start of t eatment earlier in time when tumors 
are still small, localized and more responsive to the treatments. Since earlier diagnosis may 
improve the prognosis, and necessarily not so heavy, long and expensive treatments are 
needed, the early detection service is considered to be beneficial both for the patients and 
for the health care system. On the other hand, the mass-screening service is a substantial 
financial load for the Finnish municipalities who bear the responsibility for conducting the 
screening. Other disadvantages of screening are over-diagnosis, increased anxiety for 
screened women, and the exposure to extra radiation. S nce the municipalities aim to lead 
evidence-based screening policy, the balance between pros and cons of mammography 
screening service is a continuous topic of public dis ussions. 
 
In Finland, a population-based early detection program for breast cancer was introduced in 
1987. It started gradually, but covered the whole cuntry already in early 1990s. During the 
study period 1987-2001, there was a bylaw on public health regulating the invitation 
procedure by stating that organized, free of charge mammography screening should be 
offered every second year to women aged 50-59 years, while screening of 60-69 years old 
remained optional. The Finnish invitational screening program for breast cancer in ages 50-
59 is reported to be effective [3-7], but information about potential impacts of extending to 
older and/or younger age groups or cutting the mass-screening practice on future breast 
cancer burden is required. This work is motivated by the lack of proper methodology for 
such a policy change assessment. 
 
The measures of breast cancer burden are connected with each other; when we know the 
incidence and survival of the disease, we can calculate the prevalence and mortality. 
Publications I and II included in this thesis deal with estimating and predicting the 
incidence. The third paper (III) concentrates on estimating the survival and, by utilizing the 
results presented for incidence in paper I, to predict the breast cancer mortality. Based on 
different future scenarios of mass-screening policy, alternative short-term predictions for 
incidence (I) and mortality (III) for year 2012 are presented. The methodology is mostly 
developed in publications I and III, while publication II concentrates on quantifying the 
effects of separate components of the mass-screening program on breast cancer incidence. 
Paper (IV) provides important back-up for the predictions by studying the validity of used 
predictors. It focuses on finding out how important is the role of screen-detection and 
clinical tumor characteristics in addition to cancer r gistry information in describing the 
breast cancer survival. As the only covariates used in incidence and mortality prediction 
models in addition to screening invitation are the ones that are available in the cancer 
registry, namely age, stage and calendar time, it is crucial to know how powerful they are 
and how would the predictions change if we had all the relevant information of all the 






The term ‘efficacy’ has been defined by Last [9] as “the extent to which a specific 
intervention, procedure, regimen or service produces a beneficial result under ideal 
circumstances”, contrasting with the closely related term ‘effectiveness’ defined by Last as 
“a measure of the extent to which a specific intervention, procedure, regimen or service, 
when deployed in the field in routine circumstances, does what it is intended to do for a 
specific population”. In practice, studies to evaluate mass-screening for breast cancer have 
rarely assessed efficacy or effectiveness as defined, but rather a mixture of the two, 
depending on the design and other circumstances of the study [10]. The focus of this work 
is on assessing the effectiveness of mass-screening, and, by utilizing the data on invitations, 
on showing the estimated impacts of changes in an existing screening program on the short-
term predictions. Given the screening process (2-year screening interval, attendance rate, 
rate of opportunistic screening, specificity, sensitivity etc.) what would happen to the breast 
cancer incidence and mortality in Finland if we extended the invitations to older or/and 
younger age groups or stopped the program entirely?  
 
The backbone of the policy change assessments (I-III) is the novel screening invitation 
dataset, utilized for the first time in this thesis. It is a large data matrix that includes year- 
and age-specific information whether women in each municipality were invited or not to 
have a free mammography test during time period 1987-2001. First, this database makes it 
possible to take into account the real patterns of creening that have been going on in 
municipalities; we do not have to content with assuming that every woman was screened 
regularly every second year as stated by the official recommendations. It can be expected 
that modeling based on detailed municipal invitation data will result in more accurate 
predictions than those based on country level ignorng deviations. Secondly, data on year- 
and age-level enables adequate management of the two-year mass-screening cycle; the 
years within a screening round can be separated from each other, leading to a very specific 
manner of taking the program into pieces. The programming of the future screening policy 
scenarios is facilitated by the possibility to combine these pieces to correspond to the 
desired policy. 
 
The most important indicator for the effectiveness of a mass-screening program is the 
cause-specific mortality. Screening activities without a decreasing impact on mortality are 
poorly justifiable. Even so, the incidence of breast cancer is a more acute indicator than 
mortality with respect to required health care resources. There is not much specific 
information about how the separate components (first and subsequent rounds and years 
within them, breaks, and post screening period) of an invitational mass-screening program 
differ from each other in terms of influencing the incidence. It is also reasonable to assume 
that different program components’ impact on breast cancer incidence is dependent on 







As treatments get better and curability of breast cncer has become reality, it is reasonable 
to assume that part of the patients can be considered to be healthy survivors. This 
proportion of the patient population is not at risk of dying from breast cancer and can be 
assumed to be cured of the disease in a statistical ense. Thus, cancer survival analysis, 
which had focused almost exclusively on time to death, should also focus on estimating the 
proportion of long-term survivors among the patients. Following Heinävaara and Hakulinen 
[11] and De Angelis et al. [12], the breast cancer survival is modeled by applying a 
parametric mixture model where the patient population is allowed to be a mixture of two 
subpopulations with distinct risk of dying: those patients that are cured and those that are 
bound to die of the disease. This approach provides a way of modeling the hazard of fatal 
cases and the proportion of cured cases simultaneously. The role of prognostic factors, such 
as age and screening program component at diagnosis can be evaluated separately for these 
two patient groups. In addition, the proportion of cured patients can be allowed to vary by 
covariates. In this thesis, particular interest lies on the possible differences in cure fractions 
between separate components of the mass-screening program at diagnosis. This is the first 
time a cure model is fitted to Finnish breast cancer data. 
 
To be able to die from breast cancer at a certain time point t, a patient must first stay alive 
until that. That is, not to die either from breast cancer or other causes before time t. For this 
reason we need to know the estimate for patients’ survival from other causes than breast 
cancer in addition to cause-specific survival. It would be straightforward to assume that 
breast cancer patients are a random sample and their risk to die from other causes than 
breast cancer is the same as in corresponding general population. However, earlier results 
from stomach [13] and lung cancer [11] suggest that t e risk could be significantly elevated 
and may also depend on covariates. The mortality model should therefore somehow 
account for the selection of patients with respect to general population mortality.  
 
Since one aim of this study is to present methodologies for taking into account the mass-
screening invitation information in breast cancer bu den predictions, the presented models 
are essential parts of the results. So, despite the thesis is organized in separate sections for 
methods and results, the section ‘5. Methods’ contains  considerable part of this work’s 
results. This is a typical feature for studies that pl ce themselves on the boundary between 






2. Review of the literature 
 
The efficacy of a screening program is demonstrated by changes in disease-specific 
mortality, and there is a vast literature dealing with randomised studies to evaluate the 
efficacy of mammographic breast cancer screening pro rams world-wide, best summarized 
in the Handbook by International Agency for Research on Cancer [10]. In randomised 
controlled trials, screening women aged 50-69 has been shown to reduce mortality from 
breast cancer by approximately 25% [14]. The Finnish invitational screening program for 
breast cancer in ages 50-59 has been reported to reduce breast cancers in several studies 
from years 1999 to 2008 [3-7].  
 
Studies to assess consequences of changing an existing mass-screening program are still 
rare. In their recent article, Sarkeala et al. conclude that extension of invitations to age 
group 60-69 would prevent breast cancer deaths among the elderly in Finland [15]. Moss et
al. have estimated that starting the invitations already t age 40 years would yield a non-
significant reduction in breast cancer mortality [16], and thus further follow-up is needed 
for any decisions. Impacts of mammographic screening policy alternatives on cost-
effectiveness and quality of life have been studied by de Koning et al. [17]. An early study 
in 1981 concerning public health scenarios was made by Hakulinen et al. [18], who 
evaluated effects of hypothetical changes in men’s smoking habits on lung cancer incidence 
predictions. 
 
The focus of this study is on breast cancer burden pr dictions that are usually made by 
extrapolating the trend [19]. However, trend extrapol tions may not be capable to produce 
accurate predictions when there are known factors, such as systematic screening, that might 
make abrupt changes in the temporal development of cancer incidence affecting potentially 
also the future mortality [20]. Such a sudden and upredictable change has been recently 
visible in Finnish prostate cancer rates, which increased strongly in the beginning of this 
century mostly due to widely used PSA-testing [21].  
 
Availability of a population-based registry database that includes information on screening 
invitations and/or results is not self-evident. Most f the earlier works on breast cancer 
incidence that include screening in the model assume regular screening activities as stated 
in the official guidelines [22, 23], or use estimated screening patterns [24]. The observed 
invitation schemes used in this work include also deviations from the bylaw on a 
municipality-level, which gives a more realistic picture of the true screening activities 
taking place in Finland than assuming fixed patterns.  
 
The age-period-cohort model has been widely used for analyses of cancer incidence and 





performed within a likelihood framework using the gneral age-period approach presented 
by Clayton and Schifflers [27], who also discussed the problem of non-identifiability in 
age-period-cohort models [28]. The concept of statitical cure and its maximum likelihood 
estimates were introduced by Boag in his article from 1949 [29]. Later on, De Angelis et al. 
[12] presented a mixture cure model for relative survival that incorporate background 
mortality using both exponential and Weibull survival distributions for the ‘uncured’ group. 
However, the shape parameter in the Weibull distribu ion was held constant and was not 
allowed to vary by covariates. Phillips et al. [13] introduced a parametric mixture model for 
relative survival where cancer patients’ hazard of ying from other causes did not need to 
be the same as in the corresponding group of the gen ral population. This model has been 
extended to cause-specific survival [11, 30]. Also a non-mixture cure fraction model has 
been presented and extended to incorporate the background mortality [31].   
 
Hakulinen et al. combined the predictions of incidence, general mortality and patients’ 
excess mortality together with population forecasts to predict cancer-specific mortality 
[32]. Verdecchia et al. developed a method called PIAMOD (Prevalence, Incidence, 
Analysis MODel) for the estimation of the future can er burden and illustrated it for breast 
cancer [33]. Heinävaara et al. [11] have incorporated a parametric mixture cure model into 
a model that combines incidence, cause-specific and other cause survival on individual 
level to obtain short-time predictions for lung caner prevalence and mortality. The current 
work extends the model of Heinävaara et al. by incorporating the screening invitation 
information through survival time for the uncured patients, proportion of cured, and shape 
and scale parameters of the underlying survival time distribution. The patients’ risk to die 
from other causes than breast cancer is allowed to iffer from that of a corresponding 
general population group and to depend on age and follow-up time. In addition, 
hypothetical scenarios of future screening policy are programmed and used to calculate 
alternative incidence based breast cancer mortality predictions up to 2012, and an approach 
to assess the precision of the mortality predictions based on variation in the breast cancer 







3. Aims of the thesis 
 
The aims of this study were: 
 
• To develop statistical methodology for taking historical municipality-specific 
schemes and alternative future scenarios of mass-screening into account when 
modeling and constructing predictions for incidence and mortality of breast cancer. 
(I, III)  
• To quantify the effects of separate components of an invitational screening program 
on breast cancer incidence in Finland. (I, II)  
• To produce predictions of future incidence and mortality of breast cancer in Finland 
based on alternative future scenarios of screening. (I, III)  
• To compare breast cancer survival models including o ly cancer registry variables 
with models that additionally include screen-detection information and clinical 
tumor characteristics obtained from clinical data representative of the population. 
By comparing the models it is possible to evaluate the importance of the variables 







4.1 Cancer registry data 
The breast cancer data were obtained from the Finnish Cancer Registry, which maintains a 
nation-wide database on all cancer cases diagnosed in residents of Finland since 1953. 
Almost 100% coverage of all breast cancer cases is nsured by compulsory, independent 
reporting from physicians, pathological laboratories, and hospitals, combined with 
supplementary death certificate information from Statis ics Finland.  
 
The stage of each breast cancer at diagnosis is coded at the Finnish Cancer Registry as 
follows: 0 = unreported, 1 = localized, 2 = positive regional lymph nodes, only regional 
spread, 3 = metastases, other than in regional lymph nodes, 4 = non-localized, unspecified. 
For the modeling, cases were classified to localized (stage 1), non-localized (stages 2, 3 and 
4), and unreported (stage 0) cancers.  
 
The cause of death information needed for cause-specific and other cause survival in 
publications III and IV has been separately evaluated for each patient at the Finnish Cancer 
Registry. In addition to the official cause of death received from Statistics Finland, this 
evaluation was based on the multiple subsequent clinica  notifications sent to the Registry 
concerning each case. As result, the relationship between the cancer in question and the 
official cause of death is recorded with a special ode.  
4.2 Screening invitation data 
The screening invitation data used in publications I-III were assembled from the Mass 
Screening Registry files where the registration of the Finnish screening program for breast 
cancer is centrally maintained. The Mass Screening Re istry is part of the Finnish Cancer 
Registry. The database consists of year- and cohort-specific invitation information 
(invited/no invited) during the study period 1987-2001 in each of those Finnish 
municipalities that have made an arrangement with one of the ten screening centres of the 
Cancer Society of Finland. The age range is 40-74. In year 2001, these centres covered 267 
out of 444 (60.1%) municipalities and 59.0% of 40-74 years old women in Finland. The 
mean compliance among 50-64 years old women was 90% at first screen and 93% at 
subsequent screens during the 90’s [34], so the invitation status can be assumed to reflect 
the real screening activity very well.  
 
Besides of conducting the mandatory screening of the age group 50-59, almost all 
municipalities (95%) offered some screening to age group 60-64, and 39% to age group 65-
69.  A total of 67 (25.1%) municipalities offered voluntarily screening to young women 





bylaw, such as short, irregular breaks in the screening program and delayed starting were 
rather common among municipalities. 
4.3 Database in publications I-III 
To construct the database for publications I-III, the annual screening invitation schemes 
from period 1987-2001 were linked with corresponding female breast cancer data from the 
Finnish Cancer Registry and observed (1987-2002) and predicted (2003-2012) population 
count data received from Statistics Finland. The linking was done by municipality, calendar 
year and year of birth. Since every Finnish resident has a unique personal identification 
number, the linking and follow-up of individual records is simple and reliable.  
 
Originally, the breast cancer data for publications I-III covered time period 1975-2001. 
However, the prediction base was restricted to 1987-2001 by practical reasons: the Finnish 
mass-screening program was implemented in 1987, so the incidence trend from earlier 
years was quite outdated. On the other hand, at the time of the data management process in 
spring 2004, the latest complete cancer data was from year 2001. Data from pre-screening 
years 1975-1986 were used to investigate the age-incide ce and cohort-incidence 
dependences in publication I, see section 5.1.1. For breast cancer survival in publication III, 
the patients were followed up for death until the end of 2002. Only 24 (0.1%) patients were 
lost from follow-up, mainly due to emigration. 
 
During 1987-2001 there were 907 326 women of age 40-74 in 267 Finnish municipalities 
in 13 074 cohorts included in the database (residence January 1 each year), and they 
contributed a total of 9 499 418 person-years to the study. Out of these women, 20 853 
(2.3%) were diagnosed with a breast cancer during the period 1987-2001 and, as a 
consequence, 3 499 (16.8%) of them died from breast c ncer before the end of the year 
2002, see Table 1.  
 
 
Table 1: The number of female breast cancer cases during 1987-2001 and subsequent 
breast cancer deaths during 1987-2002 in 267 Finnish municipalities (I-III). The bottom line 
displays the number of person years at risk in each age group. 
 
 40-49 50-59 60-74 Total 
 Cases Deaths Cases Deaths Cases Deaths Cases  (%) Deaths (%) 
Localized 2 510 199 4 492 269 4 748 402 11 750 (56.3) 870 (24.9) 
Non-localized 1 902 604 2 357 672 3 038 1 176 7 297 (35.0) 2 452 (70.1) 
Unreported 342 46 670 47 794 84 1 806 (8.7) 177 (5.0) 
Total 4 754 849 7 519 988 8 580 1 662 20 853 (100) 3 499 (100) 






For mortality calculations in publication III, age- and calendar year –specific expected 
survival probabilities for the Finnish general population from Statistics Finland were 
included in the database.  
4.4 Database in publication IV 
For publication IV, clinical data including all female patients diagnosed with invasive breast 
cancer during years 1996-1997 in Tampere University Hospital Area (N=483) were linked 
with corresponding registry data from the Finnish Cancer Registry. The patients were 
followed up for death until the end of year 2005. Since there was no selection of included 
patients, the data could be considered as representative of the population. The clinical dataset 
was originally collected for the EUROCARE high resoluti n studies [35]. 
 
The study database included both cancer registry and cli ical stage, see Table 2. In case of 
discrepancies between the stage and other tumor characteristics (for instance TMN-
classification) in the notification sent to Finnish Cancer Registry, the Registry staff uses the 
relevant information given in all notifications concerning the current case to reconsider the 
given stage. In these cases the stage recorded in the registry might differ from the clinical 
one. The cancer registry stage was used in the mainanalyses, but additional analyses were 
conducted to examine the quality of the registry stage.  
 
Table 2: The number of patients by stage as recorded in the cancer 
registry vs. stage in the clinical data (IV). 
 
 Clinical stage 
Cancer registry stage Localized Non-localized Unreported Total 
Localized 200 53 37 290 
Non-localized 1 151 9 161 
Unreported 16 10 6 32 
Total 217 214 52 483 
 
 
The screen-detected cases (41.9%) were defined as tumors detected by population-based 
mammography screening or by mammography control on ow  initiative. Unlike in papers I-
III, this dichotomous variable (yes/no) tells about the performance of the screening test, not 
the invitation. During years 1996 and 1997, the city of Tampere screened women up to the 
age 68 [36], while the screening policies varied betwe n the municipalities in surroundings. 
A total of 48.3% of the patients were from the city of Tampere, the rest coming altogether 
from 27 municipalities (residence January 1 in the year of diagnosis). The proportion of 
cases diagnosed as a consequence of a test taken on women’s own initiative was unknown. 
4.5 General restrictions 
Ductal carcinoma in situ (DCIS) tumors were excluded from the analyses, except in paper I, 





estimating breast cancer survival in publications III and IV, cases obtained only from death 
certificates or autopsy reports were excluded from the analyses (0.1% and 0.7% 
respectively). Women with multiple breast cancers (2.0% in III and 0% in IV) were included 






5.1 Adjustment for covariates (I-III) 
No analysis in cancer epidemiology can ignore the effect of age, and this holds especially for 
breast cancer even after restricting the analysis to women in their potential mammographic 
mass-screening ages. There has also been a distinct increase in breast cancer incidence 
during the last decades [37], so, the prediction base being 15 years, inclusion of calendar 
time is unavoidable. Calendar time is also needed to enable the extrapolation into the future. 
Moreover, in the absence of reliable registry information on cancer treatment, the calendar 
time adjusts to a certain extent for the changes in treatment practices. Since screening has – 
by definition – a different impact on the incidence of localized than non-localized breast 
cancers, and because survival from breast cancer is dependent from stage (Finnish Cancer 
Registry 2003-2005), separate incidence and survival models were built for localized and 
non-localized cases. The overall estimates for incidence were done by separate modeling of 
all cases combined group, which included also the cases with unreported stage, meanwhile 
overall mortality predictions were calculated as a combination of the stage-specific 
predictions. The other included explanatory factors were the component of screening 
program at the year of diagnosis and the university hospital region. The same predictors 
were chosen to explain both the breast cancer incide e and mortality. However, the roles of 
these factors turned out to differ from model to anther. These issues are covered in detail in 
the current section 5.1, followed by presentation of the future scenarios in section 5.2 and 
model definitions in the rest of the chapter 5. 
 
All the data management and analyses were carried out with SAS Releases 8 and 9 [38]. 
Graphs were produced with the Origin scientific graphing package, version 7.5. 
5.1.1 Age and cohort 
To exclude confounding by regular mass-screening, data from pre-screening period 1975-
1986 were used to look for a numerical function for the dependency between age and 
incidence in paper I [39]. A polynomial describing the age-incidence curve was determined 
by first fitting a simple Poisson regression model including continuous calendar time and 
numerical age as covariates. Then, one higher degree ag  term was added to the model at a 
time as long as they significantly (p<0.05) improved the fit. Comparisons between these 
nested models were done with likelihood ratio tests. As result, the age-incidence dependency 
was described with a polynomial of fourth degree both in localized and non-localized breast 
cancers. After controlling for calendar time and fourth degree polynomial age dependency, 
the cohort term was subjected to a similar procedur, but, based on likelihood ratio testing, 
there was no significant cohort effect left. This is, however, mostly due to the linear 
dependency among age, period and cohort, and does not imply that cohort itself has no effect 
on breast cancer incidence. For mortality predictions in paper III, the breast cancer incidence 





In order to account for the possible changes in age distribution of Finnish 40-74 years old 
women during the period 1987-2012, age standardization was tried for both the observed and 
predicted breast cancer incidences in paper I. The age distribution in year 2001 in the middle 
of the period was chosen to be the standard. This had, owever, no major influences on the 
incidence, and the crude rates were used in all pubications.  
 
In paper II, continuous age and cohort terms in addition to 5-year age group and calendar 
time were not needed. This was mainly due to restriction of the analysis to ages 50-74 
instead of 40-74 and using 5-year age groups instead of 10-year. After excluding the 
youngest women and adjusting for screening the relationship within 5-year age categories 
turned out to be constant. In addition, the effect of age at initial invitation was examined by 
adding into the model a variable indicating whether the municipality has started the 
invitations of a cohort before the age of 55 (33% of cohorts) or thereafter (25.5%): It showed 
marginal significance (0.05<p<0.1) in the analyses of localized cancers and all cases 
combined, but since it had no essential impact on the results it was eventually left out from 
the model. 
 
When modeling the breast cancer survival (III), the eff ct of numerical age at diagnosis was 
found to be linear on the log-scale, but categorical age in addition to numerical improved the 
fit markedly, so they were both included in the model. The categorized age defines the level 
of the group and the numerical age the change within the group. By adding the categorical 
age in the model, the effect of linear age was allowed to differ between the age categories.  
 
An interaction term was needed in both incidence models (I, II) to describe the differences 
between age groups within a program component. Becaus  the interaction was not wanted to 
take a numerical form, categorical age was used for that purpose. However, in the model for 
breast cancer survival, an interaction term between age and screening invitation component 
did not improve the fit. 
5.1.2 Screening program components 
During the observation period 1987-2001, the Finnish mass-screening service covered ages 
50-59 as mandatory and the screening cycle was two years. To be able to incorporate the 
screening invitation data into statistical models, the screening program was divided into 
components. The division was based on an assumption that different parts of an invitational 
screening program have heterogeneous impacts on breast cancer incidence (I, II). Invitation 
to mammography, as well as in the majority of women the mammography test itself, takes 
place during the first year of the screening round. If screening has an impact on breast cancer 
incidence, the incidence cannot be assumed to be constant during the whole round, and 
therefore the two years within one round were coded separately. The first screening round, 
known as the prevalence round, was also separated from the subsequent ones; the increase in 
incidence was expected to be larger during the first round compared to the subsequent ones, 





cancers [10].  In addition, the five immediate years fter the program were separated from 
the rest of the follow-up time [22], and the observed irregular breaks were identified. There 
were originally nine components in the program: 
 
1 = 1st screening round / 1st year 
2 = 1st screening round / 2nd year 
3 = Subsequent screening rounds / 1st year 
4 = Subsequent screening rounds / 2nd year 
5 = Up to 5 years after the last screening round 
6 = More than 5 years after the last round 
7 = Break 
8 = Screening round following 2-3 years after the br ak in the program /1st year 
9 = Screening round following 2-3 years after the br ak in the program /2nd year 
 
0 = Not invited  
 
The component 7 was defined as a break in a cohort’s screening program. These are 
irregular years in between the program when the municipalities have deviated from the 
guidelines; the main point is that the cohort has been screened at least once and will be 
screened again in the future. After a break of more than four years between invitations the 
coding starts with component 1 again, assuming that any carry-over effects of the last 
screening would have disappeared. Originally, there were also separate codes for the first 
round following a 2-3 years break in the program, but the cases diagnosed during that 
component were so few (0.6% of all cases) that they w re combined with the ‘normal’ 
subsequent rounds in the model-building process (I, II). The majority (87.5%) of these cases 
were localized.  
 
It should be noted that, because of the time lag between invitation to screening test and the 
evaluation of the outcome, cancers diagnosed during the breaks in this setting do not meet 
the criteria of an ‘interval cancer’, defined as can ers diagnosed clinically between the 
screening rounds among those with negative results at screening [10]. 
 
The component 0, not invited, includes all the women up to the point of first invitation. This 
component served as a baseline. In most of the municipalities, these were women below 50 
(some municipalities started the screening already at the age of 40) throughout the whole 
period 1987-2001, or above 59 at the time when screening started. Because the Finnish 
program was introduced gradually, and because the deviations from the bylaw, there were 
also cohorts that never got invited, or that were for some reason invited for the first time in 
older ages than 50. Every cohort was coded separately ccording to the municipality’s 
invitation scheme, so all women living in a municipal ty and born in the same year had the 
same invitation pattern.  
In the survival model for mortality calculations, the breast cancer deaths occurring during 





the year of diagnosis (III). When estimating the parameters of the cure model, the reduction 
of the number of parameters became unavoidable in order to provide stable estimates for 
each subgroup. Components with similar estimates were combined on the basis of 
preliminary cause-specific survival analyses. Given the stage, it turned out that the 
prevalence screening round was quite similar to the subsequent ones in terms of breast 
cancer survival, but the difference between the years within a round was very clearly 
pronounced also in explaining the survival from breast cancer. Consequently, for modeling 
the survival time, the rounds were combined but the separation of the first and second years 
remained. The first five years after the program were also combined with the second years. 
To avoid confusion, the combined components were marked with capital letters: 
 
A = 1st years 
 B = 2nd years and up to 5 years after 
 C = Break 
 D = More than 5 years after 
 
 N = Not invited 
 
Moreover, for model of the cure proportion P (section 5.5) only the first years were 
separated from the rest of the program marked with O. Again, this combination was done in 
order to ensure the convergence of the model and stable estimates. Table 3 displays the 
correspondence between the screening program components i  incidence (I, II) and survival 
models (III). Figure 2 demonstrates the connection between the program component at 
diagnosis and subsequent breast cancer deaths occurring during the follow-up years.
 
 
Table 3: The original screening program components, and corresponding components in 
incidence (I, II) and survival (III) models. P is proportion of cured patients in the overall 






 Survival time 
model (uncured) 
 Model of P 
1  1 → A A  A 
2  2 → B B → O O 
3  3 → A C → O  
4  4 → B D → O  
5  5 → B    
6  6 → D    
7  7 → C    
8 → 3      
9 → 4      







2012 73 6                          D 
2011 72 6                         D D 
2010 71 5                        B B B 
2009 70 5                       B B B B 
2008 69 5                      B B B B B 
2007 68 5                     B B B B B B 
2006 67 5                    B B B B B B B 
2005 66 4                   B B B B B B B B 
2004 65 3                  A A A A A A A A A 
2003 64 4                 B B B B B B B B B B 
2002 63 3                A A A A A A A A A A A 
2001 62 4               B B B B B B B B B B B B 
2000 61 3              A A A A A A A A A A A A A 
1999 60 7             C C C C C C C C C C C C C C 
1998 59 7            C C C C C C C C C C C C C C C 
1997 58 7           C C C C C C C C C C C C C C C C 
1996 57 4          B B B B B B B B B B B B B B B B B 
1995 56 3         A A A A A A A A A A A A A A A A A A 
1994 55 4        B B B B B B B B B B B B B B B B B B B 
1993 54 3       A A A A A A A A A A A A A A A A A A A A 
1992 53 4      B B B B B B B B B B B B B B B B B B B B B 
1991 52 3     A A A A A A A A A A A A A A A A A A A A A A 
1990 51 2    B B B B B B B B B B B B B B B B B B B B B B B 
1989 50 1   A A A A A A A A A A A A A A A A A A A A A A A A 
1988 49 0  N N N N N N N N N N N N N N N N N N N N N N N N N 













































   Calendar year of follow-up 
 
Figure 2: The connection between screening program component at diagnosis and 
subsequent model-based breast cancer deaths occurring during the follow-up in an 
example cohort born in 1939. This cohort had a 3 years’ break in screening during 1997-99, 
and the service was extended up to 65 years (scenario III).  
 
5.1.3 Region 
Finland is divided into five university hospital regions, Helsinki, Turku, Tampere, Kuopio, 
and Oulu. This region was included in the incidence models to describe the geographical 
differences that are known to exist in the baseline breast cancer incidence in Finland [37].  
 
In the model for breast cancer survival in paper III, the region term did not improve the fit 
and was consequently left out from the model. 
5.2 Future screening policy scenarios (I, III) 
Five alternative scenarios of mass-screening practices for breast cancer for time period 2005-





given municipality, calendar year and age at diagnosis to alter from scenario to another. In 
all scenarios, it was assumed that municipalities will strictly follow the guidelines, that is, 
there will be no deviations or breaks in the program. The scenarios were the following: 
 
 Scenario A: continuing to fulfill the current bylaw requirements of inviting 50-59 
years old women every second year,  
 Scenario B: expanding screening service from 50-59 to 50-65 years old,  
 Scenario C: expanding screening service from 50-59 to 50-69 years old, 
 Scenario D: expanding screening service from 50-59 to 40-65 years old women,   
 Scenario E: stopping the screening service entirely.  
 
Scenarios B and C are realistic and were actually hppening in several Finnish municipalities 
during 1987-2001. Due to lack of evidence [16], relatively low incidence rates and breast 
tissue and tumor characteristics, there were no plans to expand the mass-screening to women 
aged below 50 years in Finland, but scenario D was still thought to be of interest. Scenario E 
reflects the situation after stopping the program: those women that have been screened just 
before 2005 were first coded to be in the component 5 ‘up to 5 years after the last screening 
round’, followed by component 6 ‘more than 5 years fter the last round’, see section 5.1.2. 
Those who were to become 50 in year 2005 or thereaft r were coded as ‘not invited’. 
Scenario E was omitted from mortality predictions (III), since the observed data on breast 
cancer deaths during the post screening period weretoo sparse in women under 60 years of 
age. When predicting incidence based on scenario E, the lack of post screening data on  age 
group 50-59 was compensated by assuming the relativ risk estimate to be 1 (no effect) in 
the calculations. 
 
All changes in the screening practice were programmed to take place in the beginning of 
2005. The transitional period 2002-2004 from current practice to the future scenarios was 
programmed to follow the bylaw without any deviations. Because the observed schemes 
differed to some extent from one municipality to another, the major variations were 
accounted for when programming the transition period. For instance, if a municipality had 
invited women below 50 just before 2001, they were not coded to have their first year of the 
first round as they become 50, but the first year of a subsequent round etc.  
 
In mortality predictions in publication III, scenarios A, C and D were used and renamed with 
Roman numerals as scenario I, II and III, correspondingly. 
5.3 Incidence models (I-III) 
The modeling of breast cancer incidence in papers I-III was performed within a likelihood 
framework using the general age-period approach present d by Clayton and Schifflers [27, 
28]. The analyses were carried out using Poisson regression with a logarithmic link function. 
The models were built separately for localized, non-localized and all breast cancer cases 





In papers I and III, the stage-specific expected incidence EImya in municipality m (m=1, …, 



















mya aaaayEI δργγγγβα +++++++=        (1) 
 
Here r(m) is the university hospital region r (r=1, …, 5) to which municipality m belongs, 
s(m,y,a) is the screening invitation component s (s=0, …, 7) in municipality m in calendar 
year y for women of age a, and c(a) is the age category c (c= 40-49, 50-59, 60-74) that 
includes age a. The term )( )(),,,(
I
acaymsδ is an interaction between screening invitation statu  nd 
categorical age. Calendar year and age were treated as numerical variables, and they were 
re-scaled for the analyses so that the origin of time was fixed to 2003 and age to 40. The 
superscript I stands for incidence to avoid later confusion with corresponding parameters in 
the survival model (see section 5.5). Figure 3 shows the fit of the incidence model (1).  
 
In paper II, the breast cancer incidence was modeled similarly as in papers I and III, except 
that the age polynomial was replaced with categorical age (50-54, 55-59, 60-64, 65-69 and 
70-74), see section 5.1.1. To demonstrate the hypotetical situation where the 
municipalities had followed the official recommendations conscientiously, cumulative 
incidences for fictional regular screening programs from 50 up to 59 and 69 years were 
calculated. The term ‘regular’ indicates that women are invited every second year, and no 
breaks or other deviations from the official recommendations take place. Calculations were 
done using the age- and program component -specific risk ratio estimates obtained as a 
result from modeling the breast cancer incidence in the observed data from years  1987-
2001 including irregularities in the invitations. The estimated incidence of the non-invited 
women was used as the baseline level. The cumulative incidence (CIa) at numerical age a











iBia IRRCI ,                      (2) 
 
where RRi is the relative risk of breast cancer at age i compared to non-invited women at 
the same age, and IB,i is the breast cancer incidence estimate at age i mong the non-invited 
women. The relative risk corresponds to the regular screening program component in each 
age, for example, in the regular program from 50 to 59 the women would be invited at the 








Figure 3: Observed (black) and model-based (blue) crude incidence curves by stage, age 
at diagnosis, university hospital region and screening program component. The fit by 
region and screening component is shown only for all stages combined. The program 
components are: 1 = 1st screening round / 1st year, 2 = 1st screening round / 2nd year, 3 = 
Subsequent screening rounds / 1st year, 4 = Subsequent screening rounds / 2nd year, 5 = 
Up to 5 years after the last screening round, 6 = More than 5 years after the last round, 7 = 
Break, 0 = Not invited.   
5.4 Prediction model for incidence (I, III) 
When calculating the predictions, the calendar time s the only term in the model that is 
extrapolated beyond the range of observations. Accordingly, there were two alternative 





use the same exponential model (1) for predictions as for modeling the observed incidence. 
The problem with that model is, however, that it can lead to unrealistic exponential growth 
in incidence of a cancer site with an increasing trend like in breast cancer. In the second 
approach, the exponential growth was leveled off by replacing the exponential relationship 
between incidence and calendar time with a linear one [19]. In short time predictions like 
these, the two approaches will produce predictions that differ only slightly from each other 
(exp( (I)y) ≈ 1+ (I)y), but when the target year is further in the future, leveling off the 
exponential growth with calendar time may become crucial. The second model with linear 
calendar time was chosen for making the future predictions based on the alternative 
scenarios. 
 
The maximum likelihood estimates obtained as a result of modeling the breast cancer 
incidence (1) together with different scenarios of future screening policy (see section 5.2) 
were then plugged in to the prediction model to obtain alternative predictions for breast 
cancer incidence rates up to 2012. 
 
The overall year-specific incidence rate predictions yÎ  were derived by first calculating the 
predicted municipality-year-age-specific cancer case numbers myamyamya nIc ˆˆˆ = , where myan̂  
is the corresponding predicted number of person-years. These predicted numbers of cases 
and person-years were then summed over all municipalities and ages to obtain the 
respective year-specific figures: ∑ ∑= m a mayy cc ˆˆ and ∑ ∑= m a mayy nn ˆˆ . Finally, the 
predicted year-specific incidence rates were calculted as yyy ncI ˆ/ˆˆ = . 
5.5 Parametric mixture model for breast cancer survival (III) 
Following Heinävaara and Hakulinen [11] and De Angelis t al. [12], the cause-specific 
survival needed for calculating mortality predictions was modeled with a parametric 
mixture model where the patient population was allowed to be a mixture of two 
subpopulations with distinct risk of dying: those patients that are cured and those that are 
bound to die of the disease (III). This approach provides a way of modeling the hazard of 
fatal cases and the proportion of cured cases simultaneously. Furthermore, the prognostic 
factors can be estimated separately for these two patient groups. The modeling was done 
separately for localized and non-localized breast cncer cases.  
 
Let us assume that a proportion P of patients is cured and hence has a survival frombreast 
cancer equal to 1; the remaining proportion 1-P represents those uncured. The mixture 







( ) )(1)( 1, tSPPtS PCC −−+= ,                                                                     (3) 
 
where t is the survival time from breast cancer and PCS −1, is the breast cancer survival 
function for the uncured population. The proportion of cured P was allowed to depend on 
age category as in (1) and on a 3-class screening invitation status, see section 5.1.2 and 
Table 3. 
 
The proportion of statistically cured patients P can be described as the asymptote of the 
overall survival curve CS and the point of statistical cure for the cured population as the 
point in follow-up time when CS  reaches the level of P, that is, the point in time when CS  
approaches its asymptote. This is illustrated in Figure 4. A proportion of cured patients can 
be observed when those remaining alive can be considered to be healthy survivors with 
respect to breast cancer; the situation is essentially equivalent to the interval specific 
relative survival being equal to one or excess mortality rate to zero.  
 
Figure 4: The proportion of statistically cured patients can be defined as the asymptote of 
the survival curve, and the point of statistical cure for the cured population as the point in 
follow-up time when the curve reaches the asymptote.  
 
The expected survival times for the uncured patients were modeled as a function of year y, 
age a, age category c(a) defined as in (1), and a combined screening invitation component 
q(m,y,a) in municipality m in calendar year y for women of age a at diagnosis (see section 
5.1.2 and Table 3):  
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The log of the likelihood of the overall survival model (3) was maximized using the 
iterative Gauss-Newton method. It was assumed that only uncured patients can die from 
breast cancer. The computing was performed using the NLIN procedure in SAS [38].  
 
Selection of the probability distribution for survival time and the model-building were 
based both on likelihood ratio tests and graphical di gnostics including examination of 
(log)negative-log plots and Cox-Snell residuals. The general principle was to make the 
model as simple and robust as possible. Since the primary aim was to provide reliable 
extrapolations, the fit of model-based number of deaths curve to the observed one, 
especially towards the end of the observation period, was the most important criterion for 
the goodness-of-fit of the survival model. As a result, the two parameter gamma 
distribution was chosen both on grounds of the bestfit in both stage categories, and the 
flexibility it has in the shape of the function compared to other candidates exponential, 
Weibull, and lognormal. To allow that flexibility, the shape and scale parameters were 
expressed as functions of covariates. Figure 5 show the fit of the survival model (3) by 
covariates. 
5.5.1 Variation in breast cancer survival  
To estimate the uncertainty related with breast cancer survival (3), and especially with its 
components life expectancy for uncured (4) and proportion of cured patients, a likelihood-
based 95% confidence region was constructed 
 
( ) 2 )05.0,2(max2 ==≤− αχ dfLL ,                                    (5) 
 
where Lmax is the maximum of the log-likelihood of the overall survival model and L is a 
log-likelihood obtained by altering the values of exp cted survival time and proportion of 
cured. When calculating L, the shape and scale parameters were not changed but held fixed 
as their maximum likelihood estimates.  
 
After constructing the confidence region, different points were systematically chosen from 
the border of the region, and mortality predictions were re-calculated using corresponding 
values of life expectancy (LE) and P. The 95% confidence bounds for breast cancer 
mortality predictions related with uncertainty in breast cancer survival estimates were 

































































































































































Figure 5: Observed (black solid line) vs. model-based (blue dashed line) numbers of 
breast cancer deaths during the observation period 1987-2001 plotted by grouped age, 
numerical age, and combined screening program component. All the covariates are 
measured at diagnosis. The combined program components are: A = 1st years, B = 2nd 






5.6 Survival from other causes than breast cancer (III) 
When predicting breast cancer mortality (III), we need to estimate the patient’s other cause 
mortality as well; to be able to die from breast cancer at a certain time point t, a patient 
must first stay alive until that. That is, not to die either from breast cancer or other causes 
before time t.  
 
The cancer patients’ other cause mortality hazard could be derived directly from the general 
population life-tables. However, previous results from other cancer sites suggest that the 
cancer patients’ risk to die from other causes is not ecessarily the same as in 
corresponding general population [11, 13]. The relationship between patients’ and general 
population’s hazards might also not be constant but depend on covariates like stage of the 
tumor, age, and time passed from diagnosis. To account f r that, the ratio between patients’ 
hazard h(O) and general population’s hazard h∗ was used as a correction coefficient for the 
general population other cause mortality hazard. The general Finnish population was 
matched to the patient population by calendar year and numerical age. To assess the 
proportionality between hazards, the ratio r = h(O)/h  was modeled as a function of follow-
up period. The analysis was done using Poisson regression with a logarithmic link function 
and it was stratified by stage and age group. Figure 6 displays the observed and estimated 
hazard ratios.  
 
Figure 6: Observed (black solid line) vs. model-based (blue dashed line) ratios between 







Survival from other causes than breast cancer at follow-up time t (in years) for women 
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where h (u,v)  is the hazard to die at age u in calendar year v in the general population, and 
),( pcr  is the model-based ratio during follow-up period p (p = 1, 2, 3-5, 6-9, and 10 or 
more years after diagnosis)  for women whose age at diagnosis is included in age group c (c 
= 40-49, 50-59, 60-74).   
5.7 Mortality predictions (III) 
The breast cancer mortality was calculated as a product of the observed (1987-2001) or 
predicted (2002-2012) number of new cases (I), predict  survival from breast cancer, and 
survival from other causes (III). This was possible ecause the log-likelihoods of survival 
from breast cancer and survival from other causes ar  additive. The combination of 
incidence and patient-level survival was done by assuming that the survival is the same 
among a group of women diagnosed with a breast cancer of a certain stage, age and year, 
and during the same component of screening. 
If we denote the survival from breast cancer in a certain stage with S(C), survival from other 
causes with S(O), and the hazard to die from breast cancer with h(C), the expected number of  
breast cancer deaths D at follow-up time t (in months) in municipality m among women 
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where B(m,y,a) is the number of cancer cases of the same stage observed (1987-2001) or 
predicted (2002-2012) to occur in municipality m in calendar year y for women of age a. 
The predicted number of cases as well as the screening component in S(C)alters depending 
on the future scenario used as the basis of incidene predictions, as described in section 5.2. 
The yearly number of new cases is assumed to be evenly distributed between months, so 
the number of cases in each month is B12. The diagnosis was programmed to take place in 
the middle of the diagnosis month z. The hazard of dying from other causes than breast 
cancer was assumed to be constant during each calendar year.  
 
The overall predictions were calculated as a combinatio  of the stage-specific mortality 
predictions. However, there were 8.7% of the cases with an unreported stage in the 





unreported group consists of localized and non-localized cases in an unknown ratio. This 
ratio was estimated using relative survival, assuming that x% of the unreported cases would 
behave as localized and the rest as non-localized with respect to the relative survival. These 
proportions were then used to obtain stage-specific oefficients for calculating the overall 
number of deaths, and further the mortality. 
5.8 Cox model and relative survival (IV) 
Comparison of breast cancer survival models including only the cancer registry variables 
age and stage to models that include also screen-det ction information and clinical tumor 
characteristics was carried out with the Cox regression for cause-specific survival. In order 
to examine the robustness of the results, the same models were subjected to relative 
survival analysis to estimate the excess risk associated with breast cancer. 
 
Three hierarchical models were built to study the role of screen-detection and clinical 
tumor characteristics in addition to registry data in explaining the breast cancer survival: 
Model 1 included cancer registry variables stage of cancer (localized/non-localized) and 
age (40-49, 50-59, 60-74) at diagnosis. In addition t  Model 1, Model 2 included 
information on whether the tumor was detected by screening (yes/no). Model 3 included 
same variables as Model 2 and the following clinical variables: size of tumor (range 3-130 
mm), grade (1-3), total number of examined lymph nodes (0-29), number of metastatic 
lymph nodes (0-23), and estrogen receptor status (+/-). When modeling the relative 
survival, the follow-up time (1, 2, 3, 4, 5-10 years) was added as a factor in the models. 
 
The relative survival ratio, defined as the ratio between observed survival in the patient 
group and expected survival in a comparable group from the general population, was 
modeled using a generalized linear model with a Poisson error structure [40]. The 
assumption of proportional hazards in Cox model waschecked by adding interaction terms 
between follow-up time and other variables one at the time in relative survival Model 1. 
According to likelihood ratio testing, all the interaction terms were non-significant 
(p>0.05), indicating no need for a departure from the assumption of a constant ratio of the 






6.1 Influence of mass-screening policy changes on incidence and 
mortality predictions for year 2012 
The alternative incidence and mortality predictions for the target year 2012 are displayed in 
Figure 7. In general, the impacts of policy changes are clearly visible in the predictions for 
breast cancer incidence, while the effects on mortality re very minor. Furthermore, the 
changes influence more localized than non-localized ncidence rates, the effects on breast 
cancer mortality being the opposite.  
 
 
Figure 7: Predicted crude breast cancer incidence and mortality rates based on alternative 
screening policy scenarios. In scenario A (and I) the current practice of inviting 50-59 
years old women every second year is continued, in scenario B the screening service is 
expanded from 50-59 to 50-65, in scenario C (and II) to 50-69, and in scenario D (and III) 
to 40-65 years old women. In scenario E the screening service is stopped entirely. 
Changes in screening practice have been programmed to take place in year 2005. 
 
 
In localized cases, expansions of the screening proram increase the predicted incidence 
rates compared to continuing the current practice regularly (scenario A) (Figure 7). The 
biggest increase (13.5%) is introduced by extending the service from current practice to ten 





due to the small RR estimates for subsequent rounds/2nd years in age groups 50-59 (Table 
5), then an increase due to the ‘up to 5 years after’ estimate of 1.88 in the age group of 55-
59 (RR was assumed as 1 in calculations for age group 50-54, see page 22). After year 
2009 the ‘more than 5 years after’ estimates dominate until year 2011 when the code non-
invited (RR=1) starts to take over. The impacts of p licy changes on non-localized breast 
cancer incidence are smaller but protective; the biggest decrease (9.7%) would be achieved 
by extending to age group 40-65; the same applies to mortality, where the corresponding 
policy change would introduce a 4.5% reduction in short term predictions for non-localized 
cases compared to continuing the current practice. 
 
Table 4 shows that the overall breast cancer incidee is strongly increasing according to 
all scenarios compared to year 2001, the biggest increase suggested by scenario II. Despite 
the increasing number of new cancer cases, the predicted mortality figures remain quite 
stable. The increasing effect of mass-screening on incidence is visible when comparing the 
age group -specific rates between scenarios. For instance, when extending from current 
practice (scenario I) to older women (scenario II), the predicted incidence among the oldest 
age group increases from 362.0 to 421.4 (16.4%). The mortality predictions yielded by 
alternative scenarios are very similar: the biggest r duction is 3.0% when extending from 
the current practice to age group 40-65 (scenario III).  
 
 
Table 4. Observed and predicted overall breast cancer incidence (1/100 000 person-years) 
by age at diagnosis and mortality by age at death based on alternative mass-screening 
scenarios. In scenario I (or A) the current practice of inviting 50-59 years old women every 
second year is continued, in scenario II (C) the screening service is extended from 50-59 
to 50-69 and in scenario III (D) to 40-65 years old women. The scenarios are programmed 
to take effect in the beginning of 2005. 
 







40-49     
Incidence (cases) 158.1 (347) 227.9 (449) 227.9 (449) 239.0 (471) 
Mortality (deaths) 10.9 (24) 9.8 (19)  9.8 (19) 8.6 (17) 
50-59     
Incidence (cases) 313.7 (681) 423.5 (916) 423.5 (916) 406.9 (880) 
Mortality (deaths) 43.1 (93) 43.6 (94) 43.6 (94) 41.9 (91) 
60-74     
Incidence (cases) 303.4 (697) 362.0 (1064) 421.4 (1238) 397.7 (1169) 
Mortality (deaths) 57.4 (131) 62.6 (184) 62.4 (183) 61.7 (181) 
Total     
Incidence (cases) 258.3 (1725) 343.5 (2429) 368.2 (2604) 356.4 (2520) 







6.2 Effects of separate screening program components on breast 
cancer incidence 
The effects of separate screening program components o  breast cancer incidence at 
different ages are quantified in Table 5 as relative r sks (RR) compared to the not invited in 
the same age group (II). The interaction term betwen categorical age and screening 
program component had a strong impact both in localized and non-localized cancers, 
indicating that separate components of the screening program have different effects on the 
breast cancer incidence in different age groups. In general, the RR goes up during the first 
years of the screening rounds when the invitation and lso the mammography test takes 
place, and declines below the baseline during the second years. This effect is larger during 
the first round compared to the subsequent ones and among localized cases compared to 
non-localized. In localized cancers, RRs during the first years of all the screening rounds 
tends to increase with age, whereas in non-localized cancers the trend is the opposite. 
Because the majority of the cancers diagnosed during the first years of the screening rounds 
were localized (see Table 1), the results for localized cancers dominate the results for all 
cancers combined.  
 
During the second years – years between invitations – ri ks of invited women are clearly 
below the risk of non-invited women both for localized and non-localized breast cancers 
(Table 5). Estimates are quite stable both between localized and more advanced cases and 
among the age groups, except the very low estimate for age group 65-69 in non-localized 
cases during the 2nd years of the subsequent rounds (RR 0.19, 95%CI 0.10- .36).  
  
The post-screening effect up to 5 years after the program for localized cancers was elevated 
in the age group of 55-59, whereas it was approximately equal to the non-invited women in 
the older age groups (Table 5). In non-localized cases the RR estimates for the post-
screening period were below 1 in the age of 60-69.  
 
Figure 8 shows the model-based cumulative breast cancer incidence curves for (fictional) 
regular programs versus no screening. The term ‘regular’ indicates that women are invited 
every second year, and no breaks or other deviations from the official recommendations 
take place. In localized cancers regular invitations to screening cause 5.2% (screening up to 
59) and 28.0% (screening up to 69) extra incidence wh n cumulated over ages 50-74 
compared to situation with no mass-screening. Expanding the idealistic regular program 
from 50-59 to 50-69 would increase the cumulative incidence with 21.7%. In non-localized 
cases regular invitations up to 59 introduce a 19.8% decrease and up to 69 a 20.9% 
decrease in cumulative incidence compared to no screening when cumulated over ages 50-
74. Up to the age of 55 the cumulative incidence of n n-localized breast cancers is 





Table 5: Relative risk (RR) of breast cancer and corresponding 95% confidence interval 
(95%CI) in each component of the screening program in women aged 50-54, 55-59, 60-
64, 65-69 or 70-74 compared to non-invited women in the same age group. Cells with less 
than 12 000 person-years were excluded from analyses (-). 
 
 
Component  Localized Non-localized All combined * 
 Age RR          95%CI RR        95%CI RR        95%CI 
1st round/1st year 50-54 2.04   (1.73, 2.41) 1.77   (1.43, 2.18) 1.92   (1.69, 2.17) 
 55-59 3.03   (2.46, 3.73) 1.48   (1.13, 1.93) 2.39   (2.04, 2.80) 
 60-64 3.98   (3.06, 5.17) 1.43   (0.87, 2.33) 3.07   (2.47, 3.81) 
 65-69 - - - 
 70-74 - - - 
1st round/2nd year 50-54 0.64   (0.52, 0.78) 0.62   (0.49, 0.80) 0.62   (0.54, 0.73) 
 55-59 0.65   (0.46, 0.90) 0.53  (0.36, 0.78) 0.62   (0.49, 0.79) 
 60-64 0.59   (0.37, 0.94) 0.62   (0.37, 1.07) 0.63   (0.45, 0.89) 
 65-69 - - - 
 70-74 - - - 
Subseq. rounds/1st years 50-54 1.64   (1.39, 1.94) 1.31   (1.06, 1.62) 1.50   (1.32, 1.70) 
 55-59 2.28   (1.91, 2.72) 1.06   (0.86, 1.30) 1.76   (1.55, 2.00) 
 60-64 2.06   (1.79, 2.36) 1.01   (0.83, 1.23) 1.61   (1.45, 1.79) 
 65-69 2.63   (2.16, 3.19) 0.75   (0.52, 1.07) 1.75   (1.49, 2.06) 
 70-74 - - - 
Subseq. rounds/2nd years 50-54 0.61   (0.50, 0.75) 0.72   (0.56, 0.92) 0.67   (0.57, 0.78) 
 55-59 0.69   (0.57, 0.84) 0.52   (0.42, 0.65) 0.62   (0.54, 0.72) 
 60-64 0.45   (0.37, 0.55) 0.44   (0.35, 0.56) 0.47   (0.40, 0.54) 
 65-69 0.63   (0.45, 0.89) 0.19   (0.10, 0.36) 0.44   (0.34, 0.58) 
 70-74 - - - 
Up to 5 years after 50-54 - - - 
 55-59 1.88   (1.28, 2.77) 0.71   (0.39, 1.29) 1.33   (0.98, 1.81) 
 60-64 1.01   (0.88, 1.16) 0.81   (0.69, 0.96) 0.93   (0.84, 1.03) 
 65-69 1.10   (0.96, 1.26) 0.69   (0.58, 0.81) 0.94   (0.86, 1.04) 
 70-74 0.96   (0.71, 1.29) 0.99   (0.71, 1.38) 1.00   (0.82, 1.23) 
50-54 - - - 
55-59 - - - 
More than 5 years after 
60-64 - - - 
 65-69 0.91   (0.76, 1.08) 0.63   (0.51, 0.79) 0.80   (0.70, 0.91) 
 70-74 0.80   (0.65, 0.99) 0.79   (0.63, 1.00) 0.92   (0.80, 1.06) 
Break 50-54 1.76   (1.29, 2.40) 0.81   (0.47, 1.39) 1.27   (0.97, 1.66) 
 55-59 1.41   (1.02, 1.94) 0.79   (0.52, 1.20) 1.13   (0.89, 1.44) 
 60-64 1.32   (0.93, 1.88) 0.92   (0.57, 1.47) 1.14   (0.87, 1.49) 
 65-69 - - - 
 70-74 - - - 
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Figure 8: Model-based cumulative breast cancer incidence curves when assuming regular 
invitations in the age of 50-59 (blue dashed line) and regular invitations in the age of 50-69 
(red dashed line) versus no screening (black solid line).  
 
 
In all breast cancers combined, the cumulative incidence curve for regular invitations up to 
59 reaches the expected cumulative incidence level of the non-invited at the age of 70, 
eleven years after the last screening (Figure 8). Extending regular screening invitations to 
then age of 69 increases the overall cumulative incidence up to the age of 74 with 7.9% 
compared to the non-invited and 10.2% compared to regular screening stopped at the age of 
59. 
6.3 Effects of separate screening program components on 
proportion of cured and life expectancy for uncured patients 
Table 6 displays the estimates for proportion of cured (P) and life expectancy for uncured 
patients (LE) diagnosed in year 1995. The amount of uncertainty associated with the 
estimates is relatively high leading to wide confidence intervals and thus non-significant 
results. However, in cases diagnosed during the first years of the screening rounds the point 
estimates indicate lower (localized) or similar (non-l calized) life expectancy compared to 
non-invited. Life expectancies for cases diagnosed during the program breaks are the 
lowest in all subgroups. In general, screening increased the estimated proportions of cured 
patients both among localized and non-localized cases nd in all age groups (Table 6). The 
point estimates also decreased with age and were almost double in localized cases 









Table 6: Life expectancies for uncured breast cancer patients diagnosed in year 1995 at 
the age of 45, 55 or 65 during combined components (A, B, C, D, N) of the screening 
program, and corresponding proportions of cured patients. Estimates are provided with 
95% confidence intervals.  
 
 Age at diagnosis Life expectancy (years) Proportion of cured (%) 
Localized 45 years   
 (A) 1st years 7.7   (2.9, 20.2) 89.1   (77.2, 95.2) 
 (B) 2nd years and up to 5 years after 6.8   (2.3, 20.4) 87.4   (70.1, 95.3) 
 (C) Break 5.1   (1.3, 20.5) * 
 (N) Not invited 9.2   (5.3, 16.0) 82.5   (74.6, 88.4) 
 55 years   
 (A) 1st years 12.2   (5.4, 27.6) 85.0    (72.2, 92.5) 
 (B) 2nd years and up to 5 years after   10.9   (3.8, 31.1) 82.8    (62.7, 93.2) 
 (C) Break 8.2   (2.1, 31.9) * 
 (N) Not invited 14.7   (5.0, 42.7) 76.7    (55.7, 89.6) 
 65 years   
 (A) 1st years 11.9   (4.2, 33.7) 82.0   (61.1, 93.0) 
 (B) 2nd years and up to 5 years after 10.5   (3.5, 31.8) 79.5   (53.5, 92.9) 
 (D) More than 5 years after 8.9   (2.3, 34.7) * 
 (C) Break 7.9   (1.9, 32.8) * 
 (N) Not invited 14.3   (6.3, 32.2) 72.6   (53.9, 85.7) 
Non-localized 45 years   
 (A) 1st years 8.3   (3.6, 19.3) 51.8    (31.0, 72.0) 
 (B) 2nd years and up to 5 years after 4.9   (2.2, 11.1) 51.0    (30.7, 70.9) 
 (C) Break 7.1   (2.5, 20.3)   * 
 (N) Not invited 8.2   (5.8, 11.7) 42.8    (32.3, 53.9) 
 55 years     
 (A) 1st years 8.9   (5.0, 15.7) 48.1    (32.9, 63.6) 
 (B) 2nd years and up to 5 years after 5.2     (2.8, 9.9) 47.3    (32.0, 63.1) 
 (C) Break 7.5   (2.9, 19.4) * 
 (N) Not invited 8.7   (4.5, 16.9) 39.2    (24.5, 56.1) 
 65 years   
 (A) 1st years 8.3   (3.7, 18.7) 43.6    (24.2, 65.2) 
 (B) 2nd years and up to 5 years after 4.9   (2.4, 10.0) 42.8    (25.3, 62.4) 
 (D) More than 5 years after 9.2   (3.0, 28.1) * 
 (C) Break 7.1   (2.6, 19.3) * 
 (N) Not invited 8.2   (5.4, 12.4) 35.0    (25.5, 45.8) 
 







When using a 1% unit precision to define the equality between P and S(C), the time needed 
to reach the point of cure after the diagnosis varied from 15 to 45 years in localized, and 
from 20 to 46 years in non-localized cases diagnosed in year 1995, depending on age and 
the screening component. 
6.4 Uncertainty in mortality predictions related to breast cancer 
survival 
Stage-specific confidence regions based on likelihood ratio were constructed to feed the 
uncertainty in the estimates from the survival model (3) into mortality predictions. Both 
95% confidence regions in Figure 9 show strong negative correlation between change in LE 
and change in P. Therefore, even if there is substantial variation in the estimated values of 
LE and P (Table 6), the estimated breast cancer mortality is fairly stable as seen in Figure 
10, which shows the mortality predictions 95% confidence bounds related with uncertainty 
in breast cancer survival estimates.  In target year 2012, the confidence bounds for 
mortality caused by localized breast cancers are 8.9 – 10.6 cases / 100 000, and for 




Figure 9: Likelihood-based 95% confidence regions defined by 2(Lmax – L)  
2 (df=2, 
=0.05), where Lmax is the maximum log-likelihood and L is log-likelihood obtained by 
altering the values of expected survival time for the uncured patients (LE) and proportion 







Figure 10: The breast cancer mortality predictions made under scenario I (solid line) and 
the 95% confidence bounds related with uncertainty in breast cancer survival estimates 
(dashed line).  
 
6.5 Cancer registry vs. clinical variables as predictors for breast 
cancer survival 
The cancer registry stage and age lost some of their importance when information about 
screening and clinical tumor characteristics were added in the model of breast cancer 
survival. The effect of stage decreased and the impact of age group changed indicating that 
they both acted as a surrogate for clinical variables and mammography-detection. The level 
of surrogacy of the cancer registry stage and age was examined by comparing the predicted 
numbers of breast cancer deaths yielded by different models. The predictions between the 
model that included only the registry stage and age (Model 1) and model including also the 
clinical variables (Model 3) were approximately the same, indicating that the level of 
surrogacy was very high. It should be noted, however, that the number of events (breast 
cancer deaths) was quite limited. The screen-detection, hat is whether the tumor was 
detected by population-based mammography screening or by mammography control on 
own initiative, was found to be a significant factor when used as the only additive 
information on top of the cancer registry stage andge. The results yielded both by Cox 
regression and relative survival approaches were similar. Secondary analyses using the 
clinical data stage information instead of the stage recorded in cancer registry showed that 
in cases with dissimilar staging cancer registry stage gave a better picture of the breast 







Detailed screening invitation data were incorporated into modeling of breast cancer 
incidence and survival by defining a screening variable that gives the component of the 
screening program by municipality, year and age. The incidence rate during the observation 
period 1987-2001 was then modeled using a Poisson regression approach, giving maximum 
likelihood estimates for the parameters, including effects of the screening program 
components in different age groups (I, II). These etimates, together with hypothetical 
scenarios of future screening policy, were then used in extrapolating the model into the 
future and calculating alternative incidence predictions for breast cancer up to 2012 (I). The 
cause-specific survival was modeled by applying a parametric mixture cure model, where 
the patient population was allowed to be a combinatio  of cured and uncured patients. In 
addition to survival for the uncured, effects of covariates were also incorporated through 
the proportion of cured patients and shape and scale parameters of the survival time gamma 
distribution. The patients’ risk to die from other causes than breast cancer was allowed to 
differ from that of a corresponding general population group and to depend on age and 
follow-up time. The incidence, cause-specific and other cause survival were then combined 
and alternative short-time breast cancer mortality predictions based on hypothetical 
scenarios of future screening policy were calculated (III). Finally, the power of cancer 
registry variables stage and age as predictors for breast cancer survival was established by 
showing that they act as surrogates for clinical tumor characteristics (IV).  
 
Some strong assumptions concerning the screening data were made: First, only invitations 
to the screening test were known, not the real attendance activity. If the calendar year of 
woman’s invitation and of her breast cancer diagnosis were the same, it was assumed that 
the cancer was diagnosed as a result of mass-screening. This assumption is strong but 
seems to hold surprisingly well in our study. For extrapolations it means that an invitation 
pattern is regarded to result in a certain level of attendance which is assumed to be stable in 
the future. On the other hand, the attendance levelis known to be very high among Finnish 
women, and there is no such a reason within sight tha would change this behavior. 
Secondly, year of diagnosis together with birth year w s used to link the cancer cases with 
the invitation data. Mammographic screening is, however, a multiple-step process, starting 
with the initial mammogram and leading, if positive, to a series of more detailed 
investigations. Because the inevitable time lag betwe n invitation to screening test and the 
diagnosis, particularly women invited in the end of the calendar year might have their 
diagnosis not until the next year. There is no doubt this introduces some bias in the 
estimates, and one could think that the true differences in the screening effect sizes between 
the first actual screening year and the second year of the round are larger since some of the 






A potential confounder in estimating the effects of screening both on breast cancer 
incidence and survival is the opportunistic mammography screening performed outside the 
official mass-screening program. At least for the time being, there are no register data 
available on these activities in Finland. Using a new approach based on proportion of 
DCIS, Weedon-Fekjær has suggested that the level of opportunistic screening among 50-69 
years old women included in the Norwegian breast cancer screening program is 17.9% with 
a 95% CI of 14.4 – 23.7 [41]. In Finland, opportunistic screening includes also invitational 
mammographic tests paid by women themselves, which as become a commonplace 
practice among municipalities; in year 1997 approximately 24% of women aged 60-69 
were offered this self-paid screening service in Filand [42]. At that time, there were no 
invitations to self-paid tests for women younger than 60. However, opportunistic screening 
confounds the estimates of screening efficacy – not the assessment of policy changes, 
assuming that the level and quality of opportunistic screening remains similar to the 
situation during the observation period.  
 
The university hospital region was included as a factor in the incidence models (I, II), but 
left out from the survival model because it did notimprove the fit (III). This indicates that 
even if there is regional variation in baseline breast cancer incidence in Finland, survival 
time from breast cancer is not a function of an oncological region. This is in line with the 
fact that almost all cancer patients in Finland are treated in public hospitals which are 
obliged to follow common agreed guidelines, leading to quite homogenous treatment 
practices of cancer patients within the whole country.  Furthermore, the division by 
university hospital region is too general for studying geographical differences in the 
performance of the Finnish screening program because these differences often originate 
from dissimilarities in screening practices between municipalities. To take into account the 
variation in incidence between municipalities, we performed an additional analysis where 
the municipality was included in the model and defin d as a random variable while the 
other predictors were held fixed [43]. As expected, this resulted in some increase of the 
standard errors, but changes from the original results were minor.  
 
The effects of mass-screening were clearly visible in the estimates of the incidence of both 
localized and non-localized cancers during the active part of the programme (Table 5). The 
relative risk went up during the first years of thescreening rounds when the invitation and 
screening test (in most of the cases) took place, and declined below the baseline during the 
second years, implying that screening increases the immediate incidence of breast cancers. 
This effect was larger during the first round compared to the later ones, mainly because of 
the detection of the so called ‘prevalence pool’, which includes lesions with a long sojourn 
time [10].  In localized cancers, the relative risk during the first years of the screening 
rounds tended to increase with age, whereas in non-localized cancers the trend was the 
opposite. This may be linked with the fact that validity of screening is higher in older than 





more readily detected in a fatty breast than in young women with dense breasts [10, 44]. 
For this reason the test detects localized cancers b fore they spread and become non-
localized better in the older than in the younger age groups. 
 
The point of statistical cure, defined as the point in follow-up time when the breast cancer 
survival curve reaches the level of P, describes the amount of time needed until the only
patients that are left alive (from breast cancer) among the study population are the cured 
ones, in other words, the time needed until all patients in the ‘bound to die’ population have 
died. For example, among patients diagnosed with a non-localized cancer in year 1995 at 
the age of 55 during the first years of the screening round, it would take 36 years until the 
excess mortality associated with breast cancer has disappeared (data not shown). In a 
patient’s real life, the recovery from the disease takes place some time after the treatment. 
Therefore, the results for statistical cure point have no direct interpretation in real life and 
are presented more in a demonstrative sense than to be taken as hard facts. Also precision 
used for calculating the point of cure turned out t be very crucial due to long and flat tails 
of the survival distributions.   
 
Estimating the proportion of cured is a matter of identifiably between the cure fraction and 
the mean survival time of the uncured. Distinguishing between delayed mortality and cure 
may be a problem especially in patients with a long survival time like in breast cancer. 
However, from extrapolation point of view this makes no difference and therefore 
identifiably problems do not invalidate the use of cure models when making mortality 
predictions into the near future. Besides, even if the model fits the observed follow-up 
period well, estimates for P may be inappropriate as they are based on extrapolation of the 
parametric distribution beyond the range of the data [31].  
 
According to our results, screening increases the proportion of cured patients compared to 
the non-invited among localized cases but decreases the corresponding life expectancy for 
the uncured patients (Table 6); screening removes some patients with relatively good 
prognosis from the group of fatal cases to the group f cured ones. Since this is not 
happening in the group of non-invited women, their prognoses are better on average. 
 
The small changes in breast cancer mortality predictions after extending the screening 
program may be surprising (Figure 7). In fact, all the predictions fall within the confidence 
limits presented in Figure 10, except the prediction based on scenario III in non-localized 
cases being at the lower borderline. However, one limitation in our analysis is that the 
results are restricted to ages below 75. As both the lead and survival times in breast cancer 
are long [45], it might be that benefits of extending the program to 69 or to 65 years old 
women would be visible only above the age of 74. The results can also partly be explained 
by invitational mammographic tests paid by women themselves, which are known to be 





would explain the similarities between alternative pr dictions in full. It could be that the 
current program inviting women between ages 50-59 complemented with the (unavoidable) 
opportunistic screening is sufficient, and potential decreases in stage-specific mortality 
obtained by extending the program to older women are lso achieved by effective 
treatments [24]. As medical treatments progress, it may be that the prognoses for cancers 
detected in elderly women only when they give clinial symptoms are as good as for those 
preclinical cases detected by screening. Moreover, since most of the breast cancer deaths 
are due to metastases to other parts of the body, a critical question is when the disease 
metastasizes, and whether mammography screening is able to bring the diagnosis and 
treatment earlier in time enough to avoid the spreading of the disease.  
 
To provide some comparisons, according to predictions based on Finnish Cancer Registry 
data from year 1955-2003 there would be a total of 3488 new breast cancer cases in Finnish 
female population in age group 40-74 in year 2012 (Finnish Cancer registry); knowing that 
the study population covers 59.0% of 40-74 years-old women in Finland, the adjusted 
prediction for year 2012 would be 2058 cases. Further, to make figures comparable in situ 
tumors have to be added; if their proportion is assumed to be 3.7% as in the study database 
(see section 4.5), we end up with 2134 predicted new cases. The predictions for the age 
group 40-74 for year 2012 presented in this study (I) vary from 2234 to 2604 breast cancer 
cases between different scenarios, so they are a bit higher than the ‘official’ Finnish 
predictions.  
 
Since breast cancer mortality was calculated as a combination of different, independently 
fitted models, a common variance for the parameters in mortality model could not be 
directly calculated. As a solution, an approach where only the uncertainty related to breast 
cancer survival was taken into account was presented, leaving out the contributions of 
incidence and other cause mortality models. It was shown that despite the wide confidence 
intervals of the survival model components life expctancy and P, the uncertainty related to 
breast cancer survival was reasonable leading to fairly stable mortality estimates. This is 
due to the strong negative correlation between the changes in those components. As in 
Hakulinen and Dyba [46], the uncertainty related to the incidence analyzed with Poisson 
regression could be approximated using the delta mehod based on Taylor series expansion. 
Also bootstrapping or Bayesian approaches could be useful. The variation in the other 
cause mortality estimates consists of the error related to the population death probabilities 
and the error due to the estimates of correction coeffi ient r; the former can be assumed to 
be small and the latter was found out to be reasonable (III). In conclusion, the true 
prediction intervals of breast cancer mortality predictions are wider than the presented ones, 
the increase in uncertainty originating mainly from the incidence model. Also the precision 






During the model-building process of the cure model, the reduction of the number of 
parameters became unavoidable in order to provide stable estimates for each subgroup. As 
a consequence, components of the screening program had to be combined. This is a good 
example of practical limitations met by the researche s aiming to optimal models. Even if 
the Finnish cancer registry is one of the biggest in the world, there were not enough cases 
(or deaths) to provide the planned survival analysis because of the relatively small 
population and lack of screening information from 40% of the municipalities. The lack of 
power may prevent the detection of the modest differences. This emphasises the great value 
of nation wide cancer registries with high quality data and good coverage in countries with 
large populations for cancer epidemiological research. 
  
Economical and administrative reasons have led to the current situation where the Finnish 
municipalities are increasingly contracting the mass-screening to private institutions instead 
of the Cancer Society screening centres. Despite mandatory sending of the screening 
information to the Mass Screening Registry, arrangements are always a subject to 
negotiations and variation in the field of operators will cause considerable problems in 
maintaining the central register of screening information. This raises concerns about the 







• The impacts of screening policy changes are clearly visible on the predictions for 
breast cancer incidence in age group 40-74, while te effects on short time mortality 
predictions are minor. Furthermore, the changes would influence more localized 
than non-localized incidence rates. 
 
• Given the quality and attendance rate of the current screening process, effective 
cancer treatments, and the current rate of confounding caused by opportunistic 
screening, this study gives little support that extending the Finnish mass-screening 
service to women older than 60 would decrease the breast cancer mortality up to age 
74 in the near future. The results show no major differences between mortality 
predictions up to 2012 yielded by alternative future scenarios of the screening 
policy: Any policy change would have at the most a 3.0% reduction on overall 
breast cancer mortality compared to continuing the current practice in the near 
future. The reduction on mortality resulting from cases diagnosed as non-localized 
would be at the most 4.5%. Extensions of the program would have no significant 
impact on mortality caused by cases diagnosed as loc lized.  
 
• Extending the screening service would increase the localized but decrease the non-
localized breast cancer incidence. The biggest increase in the incidence of localized 
cases (13.5%) is introduced by extending the servic from age group 50-59 to 50-
69, and the biggest decrease in non-localized cases (9.7%) would be achieved by 
extending to the age group 40-65. 
 
• Clinical tumor characteristics are not necessarily needed when making breast cancer 
survival predictions based on a population-based cancer registry: The cancer 
registry stage and age act as surrogates for clinica  information. 
 
• Providing estimates about the uncertainty related to mortality predictions based on 
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